期刊
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
卷 28, 期 -, 页码 38-43出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ejpn.2020.07.001
关键词
Spinal muscular atrophy; Nusinersen; Onasemnogene abeparvovec; Zolgensma; Gene therapy; SMN1; SMN2
Spinal muscular atrophy (SMA) used to be one of the most common genetic causes of infant mortality. New disease modifying treatments have changed the disease trajectories and most impressive results are seen if treatment is initiated in the presymptomatic phase of the disease. Very recently, the European Medicine Agency approved Onasemnogene abeparvovec (Zolgensma (R)) for the treatment of patients with SMA with up to three copies of the SMN2 gene or the clinical presentation of SMA type 1. While this broad indication provides new opportunities, it also triggers discussions on the appropriate selection of patients in the context of limited available evidence. To aid the rational use of Onasemnogene abeparvovec for the treatment of SMA, a group of European neuromuscular experts presents in this paper eleven consensus statements covering qualification, patient selection, safety considerations and long-term monitoring. (c) 2020 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据